ITGB2 and neoplasm: ICAM1 thus acts as an immune trigger, with an opposing function to immune checkpoint proteins, and it is possible that a therapeutic enhancement of ICAM1/LFA-1 interaction between AML and T cells could enable T cell activation and tumor control.